Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142428 · ClinicalTrials.gov registry record · Phase 2
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00142428: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00142428 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142428, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The main purpose of this study is to begin to collect information and to try to learn whether or not cetuximab works in treating patients with unresectable or metastatic hepatocellular carcinoma.
Interventions
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142428
The ClinicalTrials.gov registry entry for NCT00142428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT00142428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142428 about?
NCT00142428 is a clinical study titled "Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma". The main purpose of this study is to begin to collect information and to try to learn whether or not cetuximab works in treating patients with unresectable or metastatic hepatocellular carcinoma.
What is the current status of trial NCT00142428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00142428?
The interventions under investigation include: Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00142428?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.